The following abstract is one of several parts of the thesis work submitted on September 9, 2019, to the department of Radiology, CEMBIO, University Hospital Bonn and University of Bonn. The title of the thesis work is, “Scientific Evidence for Shifting the Paradigm in Overall Management of Prostate Cancer: From Reactive Medicine to Predictive Diagnosis, Targeted Prevention, and Personalization of Medical Services.” Enough papers related to BCa are there within PubMed, and we felt lesser attention was given to PCa. We wanted to show that both of these cancers make the largest cancer pool in the world, and should be brought to the limelight.
Several of the websites to extract the information relevant for the findings are used, mainly: GLOBOCAN, ECIS, NORDCAN, SEER, Cancer Research UK, ZfKD.
In the year 2018 a total of 22,309 research materials related to BCa were indexed in PubMed while PCa accounted for just 9,516. In 2018, both BCa and PCa accounts for 11% and 10% respectively for new cases of cancer, reports GLOBOCAN. In the EU28+EFTA countries PCa incidence remain highest with the rate of 160 per hundred thousand. For BCa it is 145. The other most common site specific cancers are colorectal (71) and lung (69). PCa is reported in the age group as low as 15-19 in Europe. Studies in the UK show PCa incidence increased overall in most age groups, in the age group 25-49, it has increased by more than 400%. Cancer in young adults is even more aggressive.
Worldwide PCa and BCa account for the largest cancer incidence; mortality from both is also on par with the leading site specific cancers. Hitherto, a lot of research and publications have been done on BCa, however, ingenious effort in-relation to PCa is farce. BCa and PCa contribute about half of all the cancers in the oncological pool.